Rancak Media – , JAKARTA – Throughout November 2025, the President Director and President Commissioner of PT Medikaloka Hermina Tbk. (HEAL) were actively acquiring shares in the company.
According to disclosed information, Medikaloka Hermina President Director Yulisar Khiat executed three separate share purchase transactions for HEAL during November 2025.
Yulisar’s first recorded purchase took place on November 6, 2025, where he acquired 2.24 million HEAL shares. Valued at Rp1,442 per share, this transaction cost Yulisar Rp3.23 billion. Consequently, Yulisar increased his ownership in HEAL by 0.01%, bringing his total stake to 6.21% of the company’s shares.
He continued his buying spree on November 25, 2025, purchasing 10.26 million Medikaloka shares. The executive, who was recently appointed President Director, invested Rp14.68 billion in this particular transaction.
The following day, Yulisar once again acquired a substantial block, buying 10.32 million HEAL shares. At a price of Rp1,425 per share, this transaction represented another significant outlay of Rp14.70 billion.
These two latest transactions raised Yulisar’s total ownership to 6.35% of HEAL shares, making him the executive with the largest shareholding in the company. Despite these significant insider purchases, the Astra Group remains HEAL’s largest shareholder after public investors.
Cumulatively, by the end of November 2025, Yulisar had acquired a total of 22.83 million HEAL shares, amounting to a grand total of Rp32.61 billion. Currently, Yulisar holds 975.55 million shares of Medikaloka Hermina.
Beyond Yulisar, Medikaloka Hermina President Commissioner Hasmoro also significantly increased his stake in HEAL shares, completing five transactions during November 2025.
Specifically, on November 7, 2025, Hasmoro purchased 139,900 HEAL shares at Rp1,450 each. He followed this with a substantial acquisition of 1.38 million HEAL shares at Rp1,443 per share on November 10, 2025, and another 64,000 HEAL shares at Rp1,430 per share on November 11.
These early November transactions saw Hasmoro commit Rp2.29 billion, boosting his ownership in Medikaloka Hermina by 0.01% to 4.85%.
Hasmoro’s purchasing activities continued on November 13, 2025, when he bought 241,100 HEAL shares at a price of Rp1,420 per share.
Just one day later, on November 14, 2025, Hasmoro executed another transaction, acquiring 463,400 shares at Rp1,420 per share. The executive, who has a background in the military, invested an additional Rp658.02 million in this purchase.
As a result of these strategic moves, Hasmoro’s ownership in HEAL expanded to 4.86%, giving him control over 746.49 million shares in the company.
The specific rationale behind these substantial transactions by both HEAL top executives was not explicitly detailed. Both company leaders simply stated that the purpose of their share acquisitions was for investment in HEAL.
However, despite this strong insider confidence, HEAL shares on the stock exchange have experienced a significant correction, falling 13.80% year-to-date in 2025. Specifically for November 2025, the Hermina hospital stock also saw a 6.67% decline, trading at Rp1,400 per share in intraday trading today.
Disclaimer: This news article is not intended as an invitation to buy or sell shares. Investment decisions are solely at the discretion of the reader. Bisnis.com is not responsible for any losses or gains arising from the reader’s investment decisions.
Summary
PT Medikaloka Hermina Tbk. (HEAL) experienced significant insider share purchases during November 2025. President Director Yulisar Khiat acquired a total of 22.83 million HEAL shares across three transactions, investing Rp32.61 billion and raising his ownership to 6.35%. This makes him the executive with the largest shareholding in the company.
Concurrently, President Commissioner Hasmoro completed five transactions, substantially increasing his stake to 4.86% in HEAL. Both executives stated their purpose for these acquisitions was for investment. Despite this strong insider confidence, HEAL shares faced a significant correction, declining 13.80% year-to-date and 6.67% specifically in November 2025.
